NovoSeven
Orphan Drug Cold Chain RequiredFDA Approved
Description
NovoSeven is a recombinant coagulation factor VIIa indicated for the treatment of bleeding episodes and for the prevention of bleeding in surgical procedures in patients with rare hemorrhagic disorder due to a coagulation factors defect. It works by initiating blood clotting.
Indications & Therapeutic Use
Hemophilia A or B with inhibitors, rare hemorrhagic disorder due to a coagulation factors defect, Acquired hemophilia
Linked Diseases:
Global Availability (4 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
NovoSeven
| Generic Name | NovoSeven |
| Brands | 1 brand available |
| Active Ingredient | Eptacog beta (activated) |
| Drug Class | Hemophilia A or B with inhibitors |
| Manufacturer | Novo Nordisk |
| Dosage Forms | Powder and solvent for solution for injection |
| Medical Code | B02BD07 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00344332 |
| Countries | 4 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations5 Validated Nodes